Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results
Rhea-AI Summary
Kestra Medical Technologies (Nasdaq: KMTS) will report second quarter fiscal 2026 financial results on Thursday, December 11, 2025. Management will host a conference call at 4:30 p.m. Eastern Time with a live and archived webcast available in the investor relations "Events" section. Participants are encouraged to register on the website at least 10 minutes prior to the call start.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, KMTS gained 12.21%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.7% during that session. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $151M to the company's valuation, bringing the market cap to $1.39B at that time. Trading volume was exceptionally heavy at 5.3x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KMTS was down 0.89% while peers in Surgical & Medical Instruments & Apparatus showed mixed moves (e.g., EMBC up, PLSE and STAA down). Momentum scanner only flagged one peer stock moving up, suggesting KMTS trading reflected stock-specific positioning rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Earnings date set | Neutral | +12.2% | Scheduled Q2 FY2026 results release and conference call details. |
| Dec 02 | Equity offering priced | Negative | -6.8% | Upsized common share offering priced with defined size and proceeds. |
| Dec 01 | Equity offering launch | Negative | -8.5% | Proposed underwritten public offering of common shares announced. |
| Dec 01 | Prelim earnings update | Positive | -8.5% | Preliminary Q2 FY2026 results with strong growth and margin gains. |
| Nov 10 | Clinical study data | Positive | +0.8% | ACE-PAS real-world ASSURE study showed strong safety and effectiveness. |
Recent history shows negative reactions to equity offerings and even a sell-off on strong preliminary Q2 results, while today’s simple earnings-date notice coincided with a sharp gain.
Over the last month, KMTS reported preliminary Q2 FY2026 results with strong revenue growth and margin expansion on Dec 1, 2025, yet the stock fell following that release and the concurrent offering announcements. Subsequent offering pricing on Dec 2 also saw further weakness. In contrast, the Dec 3 notice setting the formal Q2 FY2026 reporting date and conference call aligned with a 12.21% gain. Earlier in November, publication of large real-world ASSURE study data produced a modest positive move.
Market Pulse Summary
The stock surged +12.2% in the session following this news. A strong positive reaction aligns with KMTS trading above its 200-day MA at $21.57 and near the upper half of its 52-week range, with the stock already about 16.97% below its 52-week high. Past news shows sharp moves around offerings and preliminary results, indicating sensitivity to capital and growth updates. Investors have also reacted to clinical milestones, so earnings commentary and any forward-looking detail could have influenced sustainability of upside moves.
AI-generated analysis. Not financial advice.
KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report second quarter fiscal 2026 financial results on Thursday, December 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time.
A live and archived webcast of the conference call will be available in the “Events” section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call.
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.
Investor contact Neil Bhalodkar neil.bhalodkar@kestramedical.com
FAQ
When will Kestra Medical Technologies (KMTS) report Q2 fiscal 2026 results?
What time is the KMTS Q2 fiscal 2026 conference call on December 11, 2025?
How can investors access the KMTS December 11, 2025 webcast and replay?
Do I need to register to join the KMTS December 11, 2025 conference call?
Will the KMTS Q2 fiscal 2026 call include management commentary?
